- Home
- SNTI vs RAND Comparison
SNTI vs RAND Comparison
Compare SNTI & RAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- RAND
- Stock Information
- Founded
- SNTI 2016
- RAND 1969
- Country
- SNTI United States
- RAND United States
- Employees
- SNTI N/A
- RAND N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- RAND Finance: Consumer Services
- Sector
- SNTI Health Care
- RAND Finance
- Exchange
- SNTI Nasdaq
- RAND Nasdaq
- Market Cap
- SNTI 53.6M
- RAND 44.7M
- IPO Year
- SNTI N/A
- RAND N/A
- Fundamental
- Price
- SNTI $1.91
- RAND $13.61
- Analyst Decision
- SNTI Strong Buy
- RAND
- Analyst Count
- SNTI 3
- RAND 0
- Target Price
- SNTI $9.67
- RAND N/A
- AVG Volume (30 Days)
- SNTI 292.3K
- RAND 3.5K
- Earning Date
- SNTI 11-12-2025
- RAND 11-07-2025
- Dividend Yield
- SNTI N/A
- RAND 12.15%
- EPS Growth
- SNTI N/A
- RAND N/A
- EPS
- SNTI N/A
- RAND N/A
- Revenue
- SNTI N/A
- RAND $7,966,118.00
- Revenue This Year
- SNTI N/A
- RAND N/A
- Revenue Next Year
- SNTI $150.00
- RAND N/A
- P/E Ratio
- SNTI N/A
- RAND N/A
- Revenue Growth
- SNTI N/A
- RAND 1.16
- 52 Week Low
- SNTI $1.26
- RAND $13.50
- 52 Week High
- SNTI $16.94
- RAND $31.89
- Technical
- Relative Strength Index (RSI)
- SNTI 49.03
- RAND 40.84
- Support Level
- SNTI $1.92
- RAND $13.55
- Resistance Level
- SNTI $2.29
- RAND $13.99
- Average True Range (ATR)
- SNTI 0.16
- RAND 0.31
- MACD
- SNTI -0.03
- RAND 0.02
- Stochastic Oscillator
- SNTI 0.00
- RAND 11.22
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.